Search results
20 wrz 2024 · The primary outcome of our study was the 5-year mortality rate after the prescription of ACEIs or ARBs. Secondary outcomes included the incidence of cardiac arrest, respiratory failure, heart failure, acute myocardial infarction, sepsis, and cerebral infarction.
Up to 70% of patients with advanced pulmonary sarcoidosis develop precapillary pulmonary hypertension, which is associated with a 5-year mortality rate of approximately 40%. Patients with sarcoidosis and precapillary pulmonary hypertension should be treated with therapies such as phosphodiesterase inhibitors and prostacyclin analogues.
Abstract. Due to frequent lung involvement, the pulmonologist is often the reference physician for management of sarcoidosis, a systemic granulomatous disease with a heterogeneous course. Treatment of sarcoidosis raises some issues.
Small series report 1-year survival figures of 62% to 72% and 4- to 5-year survival of 46% to 56%.45,46 In 2008, the International Society for Heart and Lung Transplantation reported on survival for 506 sarcoidosis patients transplanted between January 1990 and June 2006.44 Five-year survival was 51% and 10-year survival 31%. For comparison, 5 ...
29 lis 2022 · For most sarcoidosis patients, the disease is quiescent, mild and self-limiting but susceptibility to disease remains life-long. In around 50% of patients, sarcoidosis resolves within 6 months [20, 21], and in patients presenting with Lofgren’s syndrome, 80% resolve within 2 years [22].
11 lis 2020 · Sarcoidosis is a multi-systemic granulomatous disease. Affected individuals can show spontaneous healing, develop remission with drug treatment within 2 years, or become chronically ill. Our main goal was to identify features that are related to prognosis.
Although patients with sarcoidosis experience higher morbidity (primary graft dysfunction, prolonged postoperative mechanical ventilation, and prolonged length of stay) and higher 30-day mortality than other lung transplant recipients (106, 107), long-term outcomes (bronchiolitis obliterans syndrome, recurrent hypoxemia after LTx, median ...
